PLN-1474 Pipeline ↓ PLN-1474 is an oral, small-molecule selective inhibitor of αvβ1; in development for treatment of stage F3/F4 liver fibrosis associated with nonalcoholic steatohepatitis, or NASH. About PLN-1474 NASH is a more severe form of non-alcoholic fatty liver disease, or NAFLD. NASH is highly prevalent, affecting approximately 16.5 million adults in the United States, including approximately 3.3 million with stage F3/F4 fibrosis. The stage of fibrosis is the strongest predictor of liver-related morbidity and all-cause mortality in NASH. Patients with F3 and F4 fibrosis carry liver-related mortality risk that is 17 times and 42 times greater, respectively, than NASH patients without fibrosis. Therefore, we believe that treating F3/F4 liver fibrosis will have an impact on liver-related morbidity and all-cause mortality in NASH. Integrin αvβ1 serves as an activator of TGF-ß and its expression has been shown to be upregulated in activated hepatic stellate cells and correlated with severity of liver fibrosis. By inhibiting αvβ1, we believe PLN-1474 could have a potent direct antifibrotic effect in advanced liver fibrosis. Program Highlights Proven mechanism in NASH/liver fibrosis Preclinical activity in animal models of NASH-fibrosis (CCl4 – CDA-HFD) Potent antifibrotic effect observed in live human NASH liver tissue Favorable drug properties & pharmacokinetics Orally bioavailable with preclinical PK suggesting BID or better oral dosing Highly potent and highly selective: >100-fold αvβ1 selectivity vs. other integrins Partnered with Novartis in October 2019 Development Status First-in-human Phase 1 healthy volunteer trial currently underway Preliminary data expected in early 2021 PLN-1474 transferred to Novartis for future development World-Class Drug Development Capabilities Our highly experienced team of fibrosis and drug development experts are claiming new territory in tissue-specific therapies. Pliant's broad pipeline includes two clinical stage programs and two preclinical stage programs. Pipeline → Our Advanced Integrin Library At Pliant, we have developed an industry-leading library of over 7,000 annotated integrin-binding molecules to probe the molecular drivers of fibrotic disease. With this library, we screen for activity against newly identified targets, to create a deep well of potential drug candidates. Learn More → About Our Science Pipeline Patients Investors & Media Careers Contact Terms of Use Privacy Notice CCPA Applicant and Staff Privacy Notice Copyright © 2021 Pliant Therapeutics, Inc. | All Rights Reserved